BATAVIA, New York April 24, 2020 – First Wave Technologies, Inc. (“First Wave” “FWT” and “Company”), a medical device company developing products for the acute care and long-term care market announces it has retained Colonel (Retired) Dallas C. Hack, MD, MPH, MSS, FACMPH, FS, CPE. Dr. Hack is a brain injury expert and is board certified in Preventive Medicine with multiple degrees and certifications including a Master of Public Health (International Health – Africa) and a Master of Strategic Studies. Colonel Hack will work together with the First Wave Engineering and clinical teams as the company moves rapidly toward market entry for its disruptive medical device, IsoVENT.

Colonel(R) Hack has had a decorated medical and military career. Prior to his military career, Dr. Hack developed expertise in computer sciences and engineering, and served as Vice President for several biomedical companies. Colonel Hack directed the Combat Casualty Care Research Program (CCCRP) at the US Army Medical Research & Materiel Command (USAMRMC) from 2008 to 2014 where he led and coordinated over $2 billion in Trauma Research and Development funding (including traumatic brain injury) across all Department of Defense groups. The initiatives Dr. Hack developed have dramatically improved trauma care worldwide and have fundamentally changed the way the Food and Drug Administration regulates brain injury product development. Colonel Hack’s other appointments included (amongst many others), Command Surgeon for the Multinational Force in Iraq, Faculty Instructor at the US Army War College, and Commander of the SHAPE Healthcare Facility in Mons, Belgium. He was a highly decorated Officer throughout his distinguished military career, including being the recipient of the Bronze Star and the Legion of Merit (twice) and was honored as the 2015 Alumnus of the Year by his Medical School, Loma Linda University. Dr. Hack’s extensive clinical, R&D, Government, and new product launch expertise coupled with his familiarity with the FDA, NIH, DoD, and administrative processes will prove valuable to the entire First Wave Team and Board as the company prepares its strategy for its patented IsoVENT’s future market launch.  

First Wave’s novel IsoVENT is currently undergoing safety trials at Kaleida Health in New York and is currently under review with the FDA for an Emergency Authorization Use. Statistics demonstrate that there is a current need for approximately 500,000 – 750,000 ventilators worldwide.

First Wave’s CEO Brian Bell stated, “Colonel Hack’s experiences across clinical, operational and engineering fields is unmatched. His guidance and hands-on approach focused singerly on saving patients’ lives is already impacting our ability to engage the market with our innovative technology and we look forward to impacting many more people in the future together.” 

Colonel Dallas Hack stated, “The vast life-saving potential of the IsoVENT system was immediately attractive to me and I look forward to assisting the experienced First Wave Technologies team in realizing that potential.”

About First Wave Technologies:
First Wave Technologies, Inc. is a medical device company developing products for the acute care and long-term care market. The focus is to disrupt areas of healthcare with innovative products which have not seen meaningful change historically for the improvement of patient care. Current products are centered around improving the ease and accuracy of pharmaceutical delivery. For more information, please visit http://firstwavetechnologies.com.

Corporate Contact:
Brian Bell
Chief Executive Officer and Director
First Wave Technologies, Inc.
99 MedTech Dr. 
Batavia, New York 14020
Phone: +1 877.784.0269
E-mail: info@firstwavetechnologies.com

Investor Contact:
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications
Phone: +1.917.214.3514
Email: jzimmons@zimmonisc.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to our IsoVENT and our partnership with Canon. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with the development and commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the IsoVENT device, (5) the risk that the Company does not execute its business plan or that the companies engaged to develop and obtain regulatory approval for the IsoVENT device do not execute their plans, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.